Targeted therapies and non-small-cell lung cancer: New developments

Current Opinion in Oncology

Volumn 19, Issue 2, 2007, Pages 75-77

  Gridelli, Cesare ^a  

^a S G MOSCATI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUORO 2 METHYL 5 INDOLYLOXY) 6 METHOXY 7 [3 (1 PYRROLIDINYL) PROPOXY]QUINAZOLINE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; B RAF KINASE; BEVACIZUMAB; CARBOPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; PACLITAXEL; PEMETREXED; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; ZD 2171;

BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 33846794673     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328012a05b     Document Type: Review

References (18)

1. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2002. CA Cancer J Clin 2003; 53:5-26.
2. Parkin DM, Bray F, Ferlay J, et al. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94:153-156.
3. Gridelli C, Rossi A, Maione P. Treatment of nonsmall-cell lung cancer: state of the art and development of new biologic agents. Oncogene 2003; 22:6629-6638.
4. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001; 7:2958-2970.
5. Fukuoka M, Yano S, Giaccone G, et al. Multiinstitutional randomized phase II trial of gefitinib for previously treated patients with advanced nonsmall-cell lung cancer. J Clin Oncol 2003; 21:2237-2246.
6. Kris MG, Natale BR, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with nonsmall cell lung cancer: a randomized trial. JAMA 2003; 290:2149-2158.
7. Thatcher T, Chang A, Parikh P, et al. ISEL: a phase III survival study comparing gefitinib (Iressa) plus best supportive care (BSC) with placebo plus BSC, in patients with advanced NSCLC (NSCLC) who had received one or two prior chemotherapy regimens. Lung Cancer 2005; 49 (suppl 2):S4.
8. Gatzemeier U, Pluzanska A, Szczesna A, et al. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced nonsmall cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004; 23:617.
9. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced nonsmall-cell lung cancer. J Cin Oncol 2005; 23:5892-5899.
10. Shepherd FA, Pereira JR, Ciuleanu T, et al. Erlotinib in previously treated non small cell lung cancer. New Engl J Med 2005; 353:123-132.
11. Bezjak A, Tu D, Seymour L, et al. Symptoms improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trial Group Study BR.21. J Clin Oncol 2006; 24:3831-3837.
12. Clark GM, Cameron T, Das Gupta A, et al. Clinical benefit of erlotinib in male smokers with squamous-cell NSCLC. J Clin Oncol 2006; 24 (suppl):405s.
13. Sandler AB, Gray R, Brahmer J, et al. Randomized phase II/III trial of paclitaxel plus carboplatin with or without bevacizumab (NSC #704865) in patients with advanced nonsquamous nonsmall cell lung cancer: an Eastern Cooperative Oncology Group (ECOG) Trial - E4599. J Clin Oncol 2005; 23 (16S):1090s.
14. Heymach JV, Johnson BE, Prager D, et al. A phase II trial of ZD 6474 plus docetaxel, in patients with previously treated NSCLC: follow-up results. J Clin Oncol 2006; 24 (18S):368.
15. Gatzemeier U, Blumenschein G, Fosella F. Phase II trial of single-agent sorafenib in patients with advanced nonsmall cell lung carcinoma. J Clin Oncol 2006; 24 (18S):7002.
16. Socinski MA, Novello S, Sanchez JM. Efficacy and safety of sunitinib in previously treated, advanced nonsmall cell lung cancer (NSCLC): preliminary results of a multicenter phase II trial. J Clin Oncol 2006; 24 (18S):7001.
17. Fehrenbacher L, O'Neill V, Belani CP, et al. A phase II, multicenter, randomised trial to evaluate the efficacy and safety of bevacizumab in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride comared with chemotherapy alone for treatment of recurrent or refractory non small cell lung cancer. J Clin Oncol 2006; 24 (18S):379.
18. Gridelli C. How to combine cytotoxic and cytostatic agents. Lung Cancer 2002; S38:39.